Tirzepatide demonstrates superior weight loss results in clinical trials, with patients losing 15-22% of body weight compared to 10-15% with semaglutide, though both medications are highly effective GLP-1 options
Retatrutide mimics GLP-1 and GIP but also targets another hormone glucagon involved in hunger regulation
Nausea, reflux, and low blood sugar risk can also increase, especially early in therapy or after dose changes
If you normally inject on a weekday, consider shifting to Friday evening or Saturday morning for that first injection at the new dose
Semaglutide offers proven safety, pharmaceutical access, cardiovascular data, and good tolerability with meaningful weight loss
the injection count doubles